• February 19, 2019

Dr. Reddy's Announces the Appointment of Marc Kikuchi to Lead Its Generics Business in North America - Odessa American: Business

e-Edition Subscribe

Dr. Reddy's Announces the Appointment of Marc Kikuchi to Lead Its Generics Business in North America

Print
Font Size:
Default font size
Larger font size

Posted: Friday, February 1, 2019 9:17 am | Updated: 9:45 am, Fri Feb 1, 2019.

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Feb 1, 2019--Dr. Reddy’s Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the appointment of Marc Kikuchi as Chief Executive Officer, North America Generics. As part of the Dr. Reddy’s senior leadership team, he will be responsible for the Company’s North America Generics business and will be based in Princeton office, U.S.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190201005324/en/

Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories, Inc. (Photo: Business Wire)

“Dr. Reddy’s is a great company with a wide portfolio and remarkable heritage,” explains Kikuchi. “I am excited to join Dr. Reddy’s and look forward to leveraging my past experiences to steer the Company’s new growth areas.”

Marc has 20+ years of experience in the Pharmaceutical Industry with extensive knowledge and understanding of Generics. Marc joins Dr. Reddy’s from Zydus Pharmaceuticals, Inc. where he served as CEO, Americas since 2016. Prior to joining Zydus, he held professional leadership roles of increasing responsibility with AmerisourceBergen Corporation, Medrad Inc., PRTM, Johnson & Johnson and Incyte Pharmaceuticals. Marc holds a Bachelor’s Degree in Molecular and Cell Biology with a Biochemistry emphasis from the University of California at Berkeley and Master of Business Administration from Carnegie Mellon University in Strategy, Marketing, and Operations Management.

RDY-0219

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190201005324/en/

CONTACT: INVESTOR RELATIONS

ASHISH GIROTRA

ashishg@drreddys.com

(Ph:+609-375-9805)MEDIA RELATIONS

CALVIN PRINTER

calvinprinter@drreddys.com

(Ph: +91-40- 49002121)

KEYWORD: UNITED STATES ASIA PACIFIC NORTH AMERICA NEW JERSEY INDIA

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Dr. Reddy’s Laboratories Ltd.

Copyright Business Wire 2019.

PUB: 02/01/2019 10:17 AM/DISC: 02/01/2019 10:17 AM

http://www.businesswire.com/news/home/20190201005324/en

© 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Odessa, TX

Current Conditions

Mostly Cloudy
36°
Humidity: 60%
Winds: N at 4mph
Feels Like: 32°

Your Extended Forecast

Tomorrow

weather
High 38°/Low 30°
Partly cloudy. Lows overnight in the low 30s.

wednesday

weather
High 57°/Low 41°
Mostly sunny. Highs in the upper 50s and lows in the low 40s.

thursday

weather
High 69°/Low 41°
Mix of sun and clouds. Highs in the upper 60s and lows in the low 40s.
Online Features

Pet Central

pets

Having a pet is a lot of responsibility, and we’ll help by giving you lots of tips and tricks! More >>

Fitness

Fitness

Our fitness articles will help teach you how to work out with gym- and home-based exercises. More >>

Crosswords

Crosswords

Enjoy the crosswords challenge in our free daily puzzles, from the harder Sunday crossword to the quicker daily. More >>

Sudoku

Sudoku

Every Sudoku has a unique solution that can be reached logically. Enter numbers into the blank spaces so that each row, column and 3x3 box contains the numbers 1 to 9. More >>




  • ALL-ACCESS: Subscribe to our e-edition and premium website at myoaoa.com.
    You can read your daily newspaper without taking a walk to the driveway.
    Look back at yesterday's newspaper, or issues from months ago with our archive feature.
    Call circulation at 432-337-7670 to sign up today.